{"resourceType": "Group", "meta": {"versionId": "2", "lastUpdated": "2023-11-26T20:53:27.103Z", "profile": ["https://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"]}, "title": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "status": "active", "url": "https://fevir.net/resources/Group/179619", "id": "179619", "identifier": [{"type": {"text": "FEvIR Object Identifier"}, "system": "https://fevir.net", "value": "179619", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Brian S. Alper"}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-11-26. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619."}}, {"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method", "valueCode": "all-of"}], "description": "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged \u226518 years with cytological or histological diagnosis of mHNPC.", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "SystematicReviewEligibilityCriteria", "display": "SystematicReviewEligibilityCriteria"}]}}], "membership": "definitional", "characteristic": [{"code": {"text": "Study Design"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:01003", "display": "randomized assignment"}]}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Randomized controlled clinical trials (RCTs)"}]}, {"code": {"text": "Study Design"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:01011", "display": "Parallel cohort design"}]}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "parallel design"}]}, {"code": {"text": "Comparison"}, "valueReference": {"type": "EvidenceVariable", "display": "GroupAssignment: ADT plus docetaxel vs. ADT alone"}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"}]}, {"code": {"coding": [{"system": "http://snomed.info/sct", "code": "397669002", "display": "Age"}]}, "valueQuantity": {"comparator": ">=", "value": 18, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Types of participants.\nPatients aged \u226518 years"}, {"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method", "valueCodeableConcept": [{"text": "applied to participants in the studies"}]}]}, {"code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "valueCodeableConcept": {"text": "metastatic hormone-naive prostate cancer"}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC."}, {"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method", "valueCodeableConcept": [{"text": "applied to participants in the studies"}, {"text": " cytological or histological diagnosis"}]}]}], "type": "animal"}